CMPX vs. ELVN, SNDX, COLL, SYRE, BCYC, NTLA, RCKT, ZYME, ADPT, and GYRE
Should you be buying Compass Therapeutics stock or one of its competitors? The main competitors of Compass Therapeutics include Enliven Therapeutics (ELVN), Syndax Pharmaceuticals (SNDX), Collegium Pharmaceutical (COLL), Spyre Therapeutics (SYRE), Bicycle Therapeutics (BCYC), Intellia Therapeutics (NTLA), Rocket Pharmaceuticals (RCKT), Zymeworks (ZYME), Adaptive Biotechnologies (ADPT), and Gyre Therapeutics (GYRE). These companies are all part of the "pharmaceutical products" industry.
Compass Therapeutics vs.
Compass Therapeutics (NASDAQ:CMPX) and Enliven Therapeutics (NASDAQ:ELVN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, analyst recommendations, community ranking, earnings, dividends and profitability.
In the previous week, Compass Therapeutics had 3 more articles in the media than Enliven Therapeutics. MarketBeat recorded 5 mentions for Compass Therapeutics and 2 mentions for Enliven Therapeutics. Enliven Therapeutics' average media sentiment score of 0.62 beat Compass Therapeutics' score of 0.55 indicating that Enliven Therapeutics is being referred to more favorably in the news media.
Compass Therapeutics received 23 more outperform votes than Enliven Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Enliven Therapeutics an outperform vote while only 75.00% of users gave Compass Therapeutics an outperform vote.
Enliven Therapeutics is trading at a lower price-to-earnings ratio than Compass Therapeutics, indicating that it is currently the more affordable of the two stocks.
Compass Therapeutics has a beta of 0.92, meaning that its stock price is 8% less volatile than the S&P 500. Comparatively, Enliven Therapeutics has a beta of 1.04, meaning that its stock price is 4% more volatile than the S&P 500.
68.4% of Compass Therapeutics shares are held by institutional investors. Comparatively, 95.1% of Enliven Therapeutics shares are held by institutional investors. 28.5% of Compass Therapeutics shares are held by insiders. Comparatively, 29.2% of Enliven Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Enliven Therapeutics' return on equity of -29.46% beat Compass Therapeutics' return on equity.
Compass Therapeutics currently has a consensus price target of $11.80, suggesting a potential upside of 353.85%. Enliven Therapeutics has a consensus price target of $38.25, suggesting a potential upside of 78.16%. Given Compass Therapeutics' higher probable upside, equities research analysts plainly believe Compass Therapeutics is more favorable than Enliven Therapeutics.
Summary
Enliven Therapeutics beats Compass Therapeutics on 9 of the 15 factors compared between the two stocks.
Get Compass Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CMPX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Compass Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:CMPX) was last updated on 1/20/2025 by MarketBeat.com Staff
Free CMPX Stock Alerts